[6-K] CytoMed Therapeutics Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

CytoMed Therapeutics Limited reported that it has completed the acquisition of synergistic assets from TC BioPharm Limited. These T cell technology assets are intended to be enhanced and re-purposed to treat cancers in China and India, signaling a focus on cell-based cancer therapies in large Asian markets. The announcement was made through a press release dated November 18, 2025, which is attached as an exhibit to this Form 6-K.

Insights

Biotech transactions and strategy analyst

CytoMed has completed an asset acquisition of T cell technology aimed at cancer treatment in China and India.

CytoMed Therapeutics Limited states that it has completed the acquisition of synergistic assets from TC BioPharm Limited. The assets relate to T cell technology that CytoMed plans to enhance and re-purpose for oncology indications, indicating a focus on cell-based cancer treatments.

The disclosure highlights an intended use of these assets to treat cancers in China and India, suggesting a geographic emphasis on two large patient markets. However, the content does not specify purchase price, development stage, regulatory status, or timelines, so the scale of the transaction and its financial impact cannot be assessed from this excerpt.

The attached press release dated November 18, 2025 is identified as providing more detail on the transaction. Future company filings or releases would be needed to understand development progress of the T cell technology and any resulting commercial or clinical milestones.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On November 18, 2025, CytoMed Therapeutics Limited (the “Company”) issued a press release announcing the completion of the acquisition of synergistic assets of TC BioPharm Limited (“TCBL”) for re-purpose after enhancements to treat cancers in China and India.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Press Release dated November 18, 2025, titled: “CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India”

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: November 18, 2025	Title:	Director and Chairman

FAQ

What transaction did CytoMed Therapeutics (GDTC) announce in this Form 6-K?

CytoMed Therapeutics Limited announced the completion of the acquisition of synergistic assets from TC BioPharm Limited related to T cell technology.

What type of assets did CytoMed Therapeutics (GDTC) acquire from TC BioPharm Limited?

The company acquired synergistic assets of TC BioPharm Limited, described as T cell technology intended for enhancement and re-purpose to treat cancers.

For which markets are the acquired T cell technology assets intended by CytoMed (GDTC)?

CytoMed states that the acquired assets are intended for enhancement and re-purpose to treat cancers in China and India.

When did CytoMed Therapeutics (GDTC) announce completion of the TC BioPharm asset acquisition?

The company issued a press release on November 18, 2025 announcing the completion of the acquisition of TC BioPharm Limited’s synergistic assets.

Where can investors find more details about CytoMed’s acquisition of TC BioPharm assets?

Additional details are contained in the press release furnished as Exhibit 99.1 to this Form 6-K, titled “CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India.”

Who signed the CytoMed Therapeutics (GDTC) Form 6-K related to the TC BioPharm asset acquisition?

The report was signed on behalf of CytoMed Therapeutics Limited by CHOO Chee Kong, identified as Director and Chairman, on November 18, 2025.